HDL2 Mouse

Dobrila D. Rudnicki, X. William Yang, Russell Louis Margolis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In 2001, Margolis and colleagues described a new autosomal dominant neurodegenerative disease, Huntington disease-like 2 (HDL2), associated with a CAG/CTG repeat expansion in an alternatively spliced exon of junctophilin 3 that encodes junctophilin 3. HDL2 is a genocopy of Huntington disease (HD)-the genetic, clinical, and neuropathological features of the two diseases are similar. Although overwhelming evidence supports the hypothesis that gain-of-toxic function of expanded polyglutamine is central to HD pathogenesis, HDL2 does not appear to be primarily a polyglutamine disease. Instead, evidence from cell, animal, and human postmortem tissue indicates that HDL2 pathogenesis is multifactorial and includes gain- and loss-of-function mechanisms involving transcripts and their protein products, generated from both strands of the HDL2 locus. The similarity between HD and HDL2 suggest that HD pathogenesis may also include multitranscript, bidirectional aspects, and that looking for points of convergence between HD and HDL2 may help us to elucidate the pathogeneses of both disorders.

Original languageEnglish (US)
Title of host publicationMovement Disorders: Genetics and Models: Second Edition
PublisherElsevier Inc.
Pages573-582
Number of pages10
ISBN (Print)9780124051959
DOIs
StatePublished - Oct 29 2014

Fingerprint

Huntington Disease
Poisons
Huntington Disease-Like 2
Neurodegenerative Diseases
Exons
Proteins
junctophilin
polyglutamine

Keywords

  • Antisense transcripts
  • Huntington disease
  • Huntington disease-like 2
  • Junctophilin 3
  • Knockout mouse model
  • Loss of function
  • Polyglutamine gain-of-function
  • RNA neurotoxicity
  • Transgenic BAC mouse model
  • Trinucleotide repeats

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rudnicki, D. D., Yang, X. W., & Margolis, R. L. (2014). HDL2 Mouse. In Movement Disorders: Genetics and Models: Second Edition (pp. 573-582). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-405195-9.00034-2

HDL2 Mouse. / Rudnicki, Dobrila D.; Yang, X. William; Margolis, Russell Louis.

Movement Disorders: Genetics and Models: Second Edition. Elsevier Inc., 2014. p. 573-582.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rudnicki, DD, Yang, XW & Margolis, RL 2014, HDL2 Mouse. in Movement Disorders: Genetics and Models: Second Edition. Elsevier Inc., pp. 573-582. https://doi.org/10.1016/B978-0-12-405195-9.00034-2
Rudnicki DD, Yang XW, Margolis RL. HDL2 Mouse. In Movement Disorders: Genetics and Models: Second Edition. Elsevier Inc. 2014. p. 573-582 https://doi.org/10.1016/B978-0-12-405195-9.00034-2
Rudnicki, Dobrila D. ; Yang, X. William ; Margolis, Russell Louis. / HDL2 Mouse. Movement Disorders: Genetics and Models: Second Edition. Elsevier Inc., 2014. pp. 573-582
@inbook{df208c651fb644e7ada75ecf7cb75347,
title = "HDL2 Mouse",
abstract = "In 2001, Margolis and colleagues described a new autosomal dominant neurodegenerative disease, Huntington disease-like 2 (HDL2), associated with a CAG/CTG repeat expansion in an alternatively spliced exon of junctophilin 3 that encodes junctophilin 3. HDL2 is a genocopy of Huntington disease (HD)-the genetic, clinical, and neuropathological features of the two diseases are similar. Although overwhelming evidence supports the hypothesis that gain-of-toxic function of expanded polyglutamine is central to HD pathogenesis, HDL2 does not appear to be primarily a polyglutamine disease. Instead, evidence from cell, animal, and human postmortem tissue indicates that HDL2 pathogenesis is multifactorial and includes gain- and loss-of-function mechanisms involving transcripts and their protein products, generated from both strands of the HDL2 locus. The similarity between HD and HDL2 suggest that HD pathogenesis may also include multitranscript, bidirectional aspects, and that looking for points of convergence between HD and HDL2 may help us to elucidate the pathogeneses of both disorders.",
keywords = "Antisense transcripts, Huntington disease, Huntington disease-like 2, Junctophilin 3, Knockout mouse model, Loss of function, Polyglutamine gain-of-function, RNA neurotoxicity, Transgenic BAC mouse model, Trinucleotide repeats",
author = "Rudnicki, {Dobrila D.} and Yang, {X. William} and Margolis, {Russell Louis}",
year = "2014",
month = "10",
day = "29",
doi = "10.1016/B978-0-12-405195-9.00034-2",
language = "English (US)",
isbn = "9780124051959",
pages = "573--582",
booktitle = "Movement Disorders: Genetics and Models: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - HDL2 Mouse

AU - Rudnicki, Dobrila D.

AU - Yang, X. William

AU - Margolis, Russell Louis

PY - 2014/10/29

Y1 - 2014/10/29

N2 - In 2001, Margolis and colleagues described a new autosomal dominant neurodegenerative disease, Huntington disease-like 2 (HDL2), associated with a CAG/CTG repeat expansion in an alternatively spliced exon of junctophilin 3 that encodes junctophilin 3. HDL2 is a genocopy of Huntington disease (HD)-the genetic, clinical, and neuropathological features of the two diseases are similar. Although overwhelming evidence supports the hypothesis that gain-of-toxic function of expanded polyglutamine is central to HD pathogenesis, HDL2 does not appear to be primarily a polyglutamine disease. Instead, evidence from cell, animal, and human postmortem tissue indicates that HDL2 pathogenesis is multifactorial and includes gain- and loss-of-function mechanisms involving transcripts and their protein products, generated from both strands of the HDL2 locus. The similarity between HD and HDL2 suggest that HD pathogenesis may also include multitranscript, bidirectional aspects, and that looking for points of convergence between HD and HDL2 may help us to elucidate the pathogeneses of both disorders.

AB - In 2001, Margolis and colleagues described a new autosomal dominant neurodegenerative disease, Huntington disease-like 2 (HDL2), associated with a CAG/CTG repeat expansion in an alternatively spliced exon of junctophilin 3 that encodes junctophilin 3. HDL2 is a genocopy of Huntington disease (HD)-the genetic, clinical, and neuropathological features of the two diseases are similar. Although overwhelming evidence supports the hypothesis that gain-of-toxic function of expanded polyglutamine is central to HD pathogenesis, HDL2 does not appear to be primarily a polyglutamine disease. Instead, evidence from cell, animal, and human postmortem tissue indicates that HDL2 pathogenesis is multifactorial and includes gain- and loss-of-function mechanisms involving transcripts and their protein products, generated from both strands of the HDL2 locus. The similarity between HD and HDL2 suggest that HD pathogenesis may also include multitranscript, bidirectional aspects, and that looking for points of convergence between HD and HDL2 may help us to elucidate the pathogeneses of both disorders.

KW - Antisense transcripts

KW - Huntington disease

KW - Huntington disease-like 2

KW - Junctophilin 3

KW - Knockout mouse model

KW - Loss of function

KW - Polyglutamine gain-of-function

KW - RNA neurotoxicity

KW - Transgenic BAC mouse model

KW - Trinucleotide repeats

UR - http://www.scopus.com/inward/record.url?scp=84943279512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943279512&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-405195-9.00034-2

DO - 10.1016/B978-0-12-405195-9.00034-2

M3 - Chapter

AN - SCOPUS:84943279512

SN - 9780124051959

SP - 573

EP - 582

BT - Movement Disorders: Genetics and Models: Second Edition

PB - Elsevier Inc.

ER -